VCM
NRIX icon

Versant Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Versant Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48K Buy
+61
New +$1.04K ﹤0.01% 2598

Other funds holding NRIX

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Versant Capital Management's NRIX Position: Q2 2026 in Review

Versant Capital Management opened a new position in Nurix Therapeutics (NRIX) in Q2 2026: 61 shares worth $1.48K. The stake represents ﹤0.01% of the portfolio and ranks #2598 among its holdings.

10 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Versant Capital Management held 61 shares of Nurix Therapeutics worth $1.48K as of Q2 2026.
  • Nurix Therapeutics was a new Versant Capital Management position in Q2 2026.
  • Nurix Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2598 holding.
  • 10 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.